Skip to main content
Vivoryon Therapeutics N.V. logo

Vivoryon Therapeutics N.V. — Investor Relations & Filings

Ticker · VVY ISIN · NL00150002Q7 LEI · 3912004AMB0KGZXZYJ15 AS Manufacturing
Open in API
Filings indexed 400 across all filing types
Latest filing 2022-03-07 Investor Presentation
Country NL Netherlands
Listing AS VVY

About Vivoryon Therapeutics N.V.

https://www.vivoryon.com/

Vivoryon Therapeutics N.V. is a clinical-stage precision medicine company focused on developing first-in-class therapies by targeting post-translational modifications of proteins. The company's scientific approach centers on inhibiting glutaminyl cyclases (QPCT and QPCTL), enzymes that catalyze pyroglutamate formation, a process implicated in the progression of various diseases. Its lead product candidate, varoglutamstat, is an orally administered small molecule QPCT/L inhibitor. Vivoryon is advancing its therapeutic pipeline for patients with inflammatory, fibrotic, and neurodegenerative diseases, with a strategic focus on conditions such as chronic kidney disease.

Recent filings

Filing Released Lang Actions
Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conference
Investor Presentation Classification · 95% confidence The document is a press release dated March 7, 2022, announcing that Vivoryon Therapeutics N.V. will present at the upcoming BioCapital Europe 2022 investor conference on March 10, 2022. It details the event, presenter, and where a webcast will be available afterward. This type of announcement, informing investors about participation in an external conference, is typically classified as an Investor Presentation (IP) if it were the presentation itself, or an announcement about future investor engagement. Since the document is an announcement about *presenting* at a conference, and not a formal regulatory filing like a 10-K or an earnings release, it fits best under the category for investor-focused materials or announcements related to investor relations activities. Given the options, 'Investor Presentation' (IP) is the closest fit for content related to presenting company information to investors, even though this specific document is the announcement of the presentation rather than the presentation slides themselves. However, following Rule 2 (The 'MENU VS MEAL' Rule), if this were a short announcement about a report being available, it would be RPA/RNS. Since this is an announcement about *presenting* at an event, and not a formal report publication, and it is focused on investor engagement, 'Investor Presentation' (IP) is the most contextually relevant classification for the subject matter, although 'Regulatory Filings' (RNS) is a possibility if we strictly interpret it as a general corporate news release distributed via DGAP. Given the specific focus on an 'Investor Conference' presentation, IP is chosen as the primary intent.
2022-03-07 English
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conference
Regulatory Filings Classification · 100% confidence The document is a press release dated March 7, 2022, announcing that Vivoryon Therapeutics N.V. will present at the 'BioCapital Europe 2022' investor conference on March 10, 2022. It provides details about the conference, the presenter (CEO), and where the presentation webcast will be archived. This content directly relates to investor relations activities, specifically announcing participation in an investor conference. This aligns best with the Investor Presentation (IP) category if it were the presentation itself, but since it is an announcement *about* presenting at a conference, it falls under the general category of investor communication. Given the options, 'Investor Presentation (IP)' is the closest thematic fit for conference participation announcements, although 'Regulatory Filings (RNS)' could also apply as a general announcement. However, since the core subject is an upcoming investor event, 'IP' is often used for related communications, or 'RPA' if it were announcing the release of a document. Since this is an announcement of participation in an external event, and not a formal regulatory filing or a release of a specific company report, 'RNS' (Regulatory Filings / General Announcement) is the most appropriate fallback for investor-related news that isn't a formal financial report or proxy material. Given the context of investor conferences, 'IP' is often used broadly for investor-facing event news, but 'RNS' is the safest general regulatory announcement category for this type of news release.
2022-03-07 English
Vivoryon Therapeutics and Simcere Announce CDE Approval of Chinese Clinical Trial Application for Varoglutamstat (SIM0408, PQ912) in Patients with Alzheimer’s Disease
Regulatory Filings Classification · 100% confidence The document is a press release dated February 28, 2022, announcing that the Chinese Center for Drug Evaluation (CDE) has approved a Clinical Trial Application for the drug varoglutamstat. This type of announcement, detailing a specific regulatory milestone (CTA approval) for a drug candidate, is typically classified as a general regulatory announcement or a specific corporate event announcement. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA), and it pertains to a specific regulatory action, it fits best under the general 'Regulatory Filings' (RNS) category, as it is a formal communication of a regulatory event. It is not a declaration of voting results (DVA), director dealing (DIRS), or a capital change (CAP). Given the nature of the announcement (a partnership update regarding clinical trial progress), RNS is the most appropriate general regulatory category.
2022-02-28 English
Vivoryon Therapeutics N.V. to Participate in Upcoming Investor Conferences
Report Publication Announcement Classification · 99% confidence The document is a press release dated January 4, 2022, announcing that Vivoryon Therapeutics N.V. will participate in two upcoming conferences (H.C. Wainwright Bioconnect Conference and J.P. Morgan Health Care Conference) in January 2022. It details the dates, venues, and participants for these events. This type of announcement, which informs investors about future corporate events (like presentations at industry conferences) rather than releasing periodic financial results or mandatory regulatory reports, is best classified as a general corporate announcement. Since it doesn't fit the specific categories like ER, IR, or AGM-R, and it is a formal news dissemination via DGAP, it falls under the general Regulatory Filings/News category, which corresponds to RNS in this schema, as it is a standard corporate news release.
2022-01-04 English
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Participate in Upcoming Investor Conferences
Regulatory Filings Classification · 100% confidence The document is a short press release dated January 4, 2022, announcing that Vivoryon Therapeutics N.V. will participate in upcoming investor conferences (H.C. Wainwright Bioconnect Conference and J.P. Morgan Health Care Conference) in January 2022. It provides dates, venues, and presenter details. This type of announcement, which informs the market about management's schedule for engaging with investors, is best classified as an Investor Presentation/Engagement announcement, which aligns most closely with the 'Investor Presentation' (IP) category, or potentially a general 'Regulatory Filing' (RNS) if no other category fits. Since it is specifically about participation in investor events, 'IP' is the most specific fit, although it is not a presentation itself, but an announcement *about* participation. Given the options, and recognizing this is a standard corporate communication about investor relations activities, 'IP' (Investor Presentation) is often used broadly for investor engagement schedules, or 'RNS' as a general regulatory announcement. Since it is not a formal report (10-K, IR, ER) but an announcement of future engagement, and 'IP' covers investor-focused material, I will select 'IP'. However, because it is purely an announcement of participation rather than the presentation material itself, 'RNS' (Regulatory Filings/General Announcement) is also a strong candidate. Given the context of investor conferences, 'IP' is slightly more descriptive of the subject matter than the generic 'RNS'. I will lean towards 'IP' as it relates directly to investor engagement activities.
2022-01-04 English
Vivoryon Therapeutics Receives FDA Fast Track Designation for Varoglutamstat in Early Alzheimer's Disease
Regulatory Filings Classification · 100% confidence The document is a news release announcing that Vivoryon Therapeutics received FDA Fast Track designation for its drug candidate, varoglutamstat. It details the drug's purpose, the clinical trials, and the implications of the FDA designation. This type of announcement, which is a specific corporate update regarding regulatory progress but is not a full financial report (like 10-K or IR) or a general regulatory filing (RNS), fits best under the category of general corporate news or an announcement that doesn't fit a more specific financial/governance code. Since it is a specific, non-financial corporate event announcement, and given the available codes, it is most appropriately classified as a Regulatory Filing (RNS) as a general corporate news item disseminated via DGAP, or potentially a Legal Proceedings Report (LTR) if the FDA designation was viewed as a regulatory event, but RNS is the broader fallback for such news releases not covered elsewhere. Given the context of DGAP distribution and the nature of the news (FDA designation), RNS is the most suitable general regulatory/corporate news category.
2021-12-22 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.